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Urinalysis had 4 protein with 5 red blood cells/high-power
field along with granular and waxy casts. A 24-hour urine collec-
tion contained 8.2 g of protein, and the creatinine clearance was
42 mL/min. The sedimentation rate was 64 mm/h; rheumatoid
factor and ANA were normal; C3, 135 mg/dL; C4, 41 mg/dL;
and both urine and serum immunoelectrophoresis were nega-
tive for paraproteins. A rapid plasma reagin test (RPR) was non-
reactive. Hepatitis B surface antigen was negative as was an
ELISA evaluation for HIV antibody. A chest radiograph dem-
onstrated her heart to be normal in size, and her lungs were
clear, but bilateral pleural effusions were noted. An ultrasound
of the kidneys demonstrated them to be normal in size and
echogenicity. The renal arteries and veins were patent.
A sodium- and water-restricted diet was prescribed, and the
patient was treated with furosemide with good response. She
underwent a percutaneous renal biopsy 3 weeks after presen-CASE PRESENTATION
tation. At the time of the biopsy, her blood urea nitrogen was
A 53-year-old African American woman who had previously 29 mg/dL; serum creatinine, 3.2 mg/dL; serum albumin, 1.1
been in excellent health presented 11 years ago with increasing
g/dL; and cholesterol, 784 mg/dL.weight, leg edema, and facial swelling that had developed over
The renal biopsy revealed 17 glomeruli by light microscopy;one month. She had no history of sickle cell disease, recurrent
one was hyalinized. The remaining glomeruli manifested mildlyurinary tract infections or pyelonephritis, vesicoureteral reflux,
increased mesangial matrix and cellularity. The glomerular base-diabetes mellitus, hypertension, renal or systemic diseases, or
ment membranes were thin and delicate, and the capillary loopsmorbid obesity. There was no family history of hypertension
were patent. One glomerulus had a segmental scar with hyalino-or renal disease. She had not been taking any prescribed medi-
sis, and a second glomerulus had a segmental scar with a smallcations nor had she been using nonsteroidal anti-inflamma-
adhesion to Bowman’s capsule. Acute tubular necrosis and inter-tory agents.
stitial edema were evident but no significant tubulointerstitialPhysical examination revealed: blood pressure, 120/84 mm Hg;
atrophy or fibrosis was seen. Immunofluorescence examinationno skin rashes; lungs were clear; cardiac examination was nor-
of the tissue was negative. Electron microscopy disclosed dif-mal; no hepatosplenomegaly; and no significant lymphadenop-
fuse foot process fusion with villous transformation; no elec-athy. Her joints were unremarkable but she had 3 pre-tibial
tron-dense deposits were seen in the mesangium or along theedema bilaterally. Laboratory evaluation demonstrated a blood
capillary wall.urea nitrogen of 32 mg/dL; serum creatinine, 1.8 mg/dL; albu-
The patient was given oral prednisone, 60 mg/day; 2 weeksmin, 1.6 g/dL; and cholesterol, 612 mg/dL. Hemoglobin was 14.6
later her serum creatinine had fallen to 0.9 mg/dL but the protein-g/dL with a normal white blood cell count and platelet count.
uria had risen to 12.4 g/day. However, after 2 months of high-
dose steroid therapy, the proteinuria had decreased to 0.1 g/day,
the serum albumin level was 3.8 g/dL, and the cholesterol levelPortions of this article are republished with permission from Korbet
was down to 326 mg/dL; she was edema free. A steroid taperSM: Primary focal segmental glomerulosclerosis, in Therapy in Nephrol-
was completed over an additional 2 months. One week afterogy and Hypertension: A Companion to Brenner and Rector’s The Kidney
(2nd ed), edited by Brady RJ, Wilcox CS, Philadelphia, W.B. Saunders discontinuing steroids she had a relapse of the nephrotic syn-
(in press). drome (13.6 g/day) but again responded to a second course of
high-dose prednisone with a complete remission. She remainedThe Nephrology Forum is funded in part by grants from Amgen,
in a complete remission for 4 months after the discontinuationIncorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
of steroids and then relapsed a second time (proteinuria of 13rated; and Bristol-Myers Squibb Company.
g/day). She was treated with prednisone and oral cyclophospha-
Key words: end-stage renal disease, proteinuria, interstitial fibrosis, mide (2 mg/kg/day) for 2 months; this regimen again produced
nephrotic syndrome. a complete remission. Eleven years after her diagnosis she re-
mains in complete remission with a serum creatinine of 0.7 mg/dL, 2002 by the International Society of Nephrology
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Table 1. Classification of FSGS in primary FSGS is based almost entirely on retrospec-
tive analyses. However, we have gained important in-Primary (idiopathic) FSGS
Familial FSGS sights into the prognosis and therapeutic response of
Secondary FSGS primary FSGS.Secondary to reduced nephron mass/glomerular adaptations
Reflux nephropathy
PathogenesisRenal dysplasia
Oligomeganephronia The etiology of primary FSGS is unknown [12, 14],Morbid obesity
but pathologic studies have implicated podocyte injurySickle cell disease
Primary glomerular diseases in the pathogenesis of segmental sclerosis in diverse dis-
Secondary to hereditary nephropathies eases including HIV-associated nephropathy [15], com-Secondary to focal proliferative glomerulonephritis
pensatory hypertrophy [16], and genetic mutations suchHIV-associated nephropathy
Heroin-associated FSGS as those involving the podocin and WT1 genes [17]. Since
the same mechanism might be responsible for primary
FSGS and recurrent disease in renal transplants, the simi-
lar podocyte pathology seen in recurrent FSGS provides
serum albumin of 3.8 g/dL, and a cholesterol of 143 mg/dL. Her
us with a unique opportunity to study the early phaseonly medications are enalapril, 2.5 mg/day, and atorvastatin, 10
of FSGS and the pathogenesis of the glomerular lesions.mg/day.
The frequency and speed with which proteinuria re-
curs in some patients receiving allografts for end-stage
DISCUSSION FSGS support the hypothesis that a circulating factor is
responsible for the glomerular injury that ultimatelyDr. Stephen M. Korbet (Professor of Medicine, Sec-
tion of Nephrology, Rush Presbyterian St. Luke’s Medical leads to FSGS. The presence of a “permeability factor”
has been demonstrated in some patients with primaryCenter, Chicago, Illinois, USA): Primary focal segmental
glomerulosclerosis (FSGS) is defined clinically by the FSGS. When the permeability factor activity level is high,
it has predicted recurrent disease [18]. The mechanismpresence of proteinuria, often in the nephrotic range, and
pathologically by segmental glomerular scars involving by which the permeability factor injures the podocyte is
unknown, but experimental evidence suggests that directsome but not all glomeruli. The clinical implications of
this lesion were first recognized by Rich in 1957 [1]. injury to the podocyte can cause both proteinuria and
glomerular scarring [14]. Plasmapheresis or immunoad-Focal segmental glomerulosclerosis is distinguished from
minimal change disease by hematuria, hypertension, and sorption early in the course of recurrent disease effec-
tively reduces the serum permeability activity and hasrenal insufficiency at presentation, poor response to ste-
roid therapy, and a progressive course to end-stage renal led to a reduction/remission in proteinuria and improve-
ment in glomerular epithelial changes [18–20].disease [2]. Although an identical glomerular lesion oc-
curs in a number of clinical settings with a presentation Serial renal biopsies from patients with recurrent FSGS
demonstrate a pathogenetic sequence beginning with po-indistinguishable from primary FSGS, the pathogenesis
and treatment of these disorders can differ significantly. docyte pathology that progresses to segmental scars and
adhesions [21, 22]. Whereas nephrotic-range proteinuriaThus, secondary causes must be excluded before making
the diagnosis of primary FSGS (Table 1). can appear within minutes of transplantation in recurrent
FSGS, glomerular pathology from biopsies performedPrimary FSGS accounts for up to 35% of glomerular
lesions in proteinuric children and adults [3–8], and the within one month of recurrence sometimes show only
foot process effacement [21, 22]. The first lesion seen byprevalence of this lesion in black patients (36 to 80%)
is two to four times the prevalence in white patients (14 light microscopy is segmental collapse of the glomerular
capillaries with proliferation and hypertrophy of the sur-to 24%) [3, 4, 6, 8, 9]. The incidence of primary FSGS
has increased two- to threefold over the last 20 years rounding podocytes. Fibrotic scars with adhesions be-
tween the involved portions of the glomerulus and Bow-[8, 10, 11], and this increase is due in part to the inclusion
of a spectrum of glomerular lesions or “variants” under man’s capsule are not seen until later in the course,
and presumably they represent evolution of capillarythe diagnosis of primary FSGS [11, 12].
Primary FSGS is now one of the leading causes of collapse and podocyte pathology.
renal failure and end-stage renal disease in the United
PathologyStates [13]. The progressive nature of primary FSGS and
its high recurrence rate in transplanted kidneys [11] has The glomerular lesion of “classic” FSGS is character-
ized by a focal segmental scar. The involved glomerularled to an increasing interest in the therapeutic approach
to patients with this lesion. More than 40 years after the capillaries are obliterated by a collagenized scar and col-
lapsed, wrinkled basement membranes. Sometimes oneoriginal description of this clinicopathologic entity, our
knowledge of the presentation and response to treatment sees a dense fibrous scar between the involved segment
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Table 2. Presenting features sented with a serum creatinine of2.0 mg/dL compared
to 10% of patients with classic FSGS [26].Children % Adults %
N  506 N  786
Clinical courseNephrotic 88 76
Male gender 54 62 The degree of proteinuria at presentation has consis-
Hypertensive 140/90 mm Hg 26 43
tently been of prognostic significance [31–33]. The pres-Hematuria 5 cells/hpf 50 40
Renal insufficiency SCr 1.3 mg/dL 19 34 ence of nephrotic-range proteinuria predicts outcome in
primary FSGS, with 50% of patients reaching end-stageReproduced with permission from Ref. 2.
renal disease (ESRD) over 5 to 10 years [31–33]. Patients
with massive proteinuria (10 g/24 h) have an even more
malignant course, with essentially all patients progress-
and Bowman’s capsule. In many cases, the scar contains ing to ESRD within 5 years [31, 34]. This outcome con-
areas of hyalinosis. The uninvolved portions of the glo- trasts with the more favorable prognosis in patients with
meruli with segmental scars, and the remaining glomeruli non-nephrotic-range proteinuria, in whom renal survival
in the biopsy are essentially normal. Although FSGS is surpasses 80% after 10 years [31–33]. An additional clini-
not an immunoglobulin-mediated disease, deposits of cal feature of prognostic significance is the serum creati-
IgM and the C3 component of complement are fre- nine at presentation. The level of serum creatinine bears
quently seen within the segmental scars and concentrated an inverse relationship to the time for progression to
in the hyalinosis lesions. Ultrastructurally, foot process ESRD; patients having a serum creatinine 1.3 mg/dL
effacement is present, both in involved and uninvolved manifest a significantly poorer renal survival than do
glomeruli. The degree of foot process effacement is vari- those whose serum creatinine is 1.3 mg/dL [4, 32, 33].
able [12, 14, 23, 24]. Some researchers have suggested that racial differ-
A number of histologic features can occur with FSGS, ences affect the course of primary FSGS. Ingulli and Te-
including mesangial hypercellularity, foam cells, mesan- jani found that 78% of black nephrotic children with
gial deposits of IgM, the segmental scar in the glomeru- FSGS progressed to ESRD over an 8.5 year follow-up
lus, hyalinosis, and pathologic changes in the podocytes. compared with only 33% of white patients [4]. This expe-
Several of these are referred to as variants of primary rience has been confirmed by some [35], but not all,
FSGS [12, 23, 24]. The cellular, or collapsing, lesion has studies in children with FSGS [36]. In our own experience
prompted much interest [10, 23, 25–27]. This lesion, de- with adults, black patients tend to present less often with
fined by segmental or global collapse of glomerular capil- non-nephrotic-range proteinuria than do white patients
laries, often contains foam cells and is associated with (14 vs. 52%) and in this respect might have a poorer
hypertrophy and hyperplasia of the surrounding visceral prognosis [32, 33]. However, when evaluating nephrotic
glomerular epithelial cells. When the cellular lesion is patients, we found no significant racial difference in the
isolated to the take-off of the proximal tubule, it has rate of decline of renal function or the number of patients
been called a tip lesion. reaching ESRD [32, 33].
Multivariate analyses of baseline clinical features have
Clinical presentation often demonstrated that only the level of serum creati-
The presenting feature in all patients with primary nine, and not proteinuria, can predict progression to end-
FSGS is proteinuria that frequently results in the ne- stage renal disease [27, 31, 33]. This finding might be
phrotic syndrome, but a non-nephrotic presentation is explained by the unusually high rate of remission and
not unusual, particularly in adults (Table 2). In addition, the associated improvement in long-term renal survival
microscopic hematuria, hypertension, and renal insuffi- in the nephrotic patients reported in these studies [27,
ciency are common presenting features [28, 29]. The 28, 33]. When patients entering a remission are elimi-
presentation for patients with primary FSGS can differ nated from analysis, both proteinuria and serum creati-
among the histologic variants, however. In contrast to nine become predictive [33].
patients with classic FSGS, patients with the cellular Studies of the prognostic importance of various patho-
lesion are more likely to be black and nephrotic at pre- logic features have disclosed that neither the proportion
sentation [10, 26, 27, 30]. Massive proteinuria (10 g/day) of glomeruli with segmental scars nor the proportion of
at presentation is much more common among patients glomeruli with global sclerosis is predictive of outcome.
with the cellular lesion (44 to 67% of patients) than in The histologic feature that has most consistently been
patients with classic FSGS (4 to 11%). Furthermore, predictive of a poor prognosis is the presence of advanced
although the time from presentation to biopsy is signifi- (20%) interstitial fibrosis [23, 27, 33, 37]. Studies have
cantly shorter, patients with the cellular lesion present shown that the presence of the cellular lesion also por-
with more advanced renal insufficiency. In one series, tends a significantly poorer prognosis than that of classic
FSGS [10, 26, 27, 30, 38]. Initial studies suggested thatmore than 60% of patients with the cellular lesion pre-
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Table 4. Response to treatment in adultsTable 3. Prognosis according to response to treatment
Patients progressing to ESRD Complete Partial No Follow-up
Author [Ref] Year N remission remission response years
Follow-up Complete Partial No
years remission remission response Nagai [48] 1994 9 4 (44%) 1 (11%) 4 (44%) 2.5
Rydel [33] 1995 30 10 (33%) 5 (17%) 15 (50%) 5.2
Adults 5.5 2/119 (1.7%) 9/67 (13%) 94/175 (54%) Cattran [41] 1998 17 8 (47%) 0 9 (53%) 11.25
Children 7.0 10/70 (14%) 0/12 (0%) 60/161 (37%) Ponticelli [37] 1999 80 29 (36%) 13 (16%) 38 (48%) 7.0
Total — 12/189 (6%) 9/79 (11%) 154/336 (46%) Schwartz [27] 1999 42 14 (33%) 8 (19%) 20 (48%) 6.25
Reproduced with permission from Ref. 2.
The early experience with steroid therapy in nephroticpatients with the tip lesion had a better response to
adults with primary FSGS was quite disappointing. Com-therapy and a more benign clinical course than did pa-
plete remission rates of20% were observed in virtuallytients with classic FSGS lesions [39, 40]. However, a
every study published prior to 1980. In 50% of these re-number of investigators have determined that the re-
ports, no patient attained a complete remission. Givensponse to treatment and renal survival did not differ
this experience, it is not surprising that nephrologistssignificantly in FSGS patients with or without the tip
became less than enthusiastic or even reluctant to subjectlesion [11, 23, 24].
their adult patients with primary FSGS to a course of
steroids or immunosuppressive therapy. This is evidentRemission
in the study by Pei et al [28], who found that only 42%
Of all the clinical and histologic characteristics evalu- of nephrotic adults with primary FSGS received treat-
ated in primary FSGS, only remission of proteinuria pre- ment, as compared to 95% of children.
dicts a favorable outcome in nephrotic patients with pri- Since 1980, however, the response to treatment in
mary FSGS [27, 28, 33, 37, 41]. In nephrotic adults and adult FSGS has improved significantly (Table 4). More
children alike, fewer than 15% of patients entering a com- than 80% of studies have reported complete remission
plete or partial remission progress to ESRD, whereas as rates in excess of 30%, with the majority being 40%.
many as 50% of persistently nephrotic patients progress We can gain insight into the marked dichotomy in remis-
to ESRD over 5 years (Table 3). Unfortunately, sponta- sion rates by comparing the treatment protocols used in
neous remissions are rare, occurring in less than 5% the studies having 30% complete remission rates with
of nephrotic patients with primary FSGS [27, 41]. But those attaining 30%. The most obvious difference was
patients receiving a course of treatment with steroids the duration of therapy, as the initial dose of prednisone
are 4 to 10 times more likely to enter a remission than utilized has been similar, ranging from 0.5 to 2.0 mg/kg/
are untreated patients [27, 37]. Because no clinical or day. The total duration of therapy in the studies that
histologic feature at presentation allows one to predict yielded a poor response rate was 2 months compared
which patients will enter a remission, the response to to an average of 5 to 9 months in studies achieving high
treatment becomes the best clinical indicator of outcome remission rates. Ponticelli et al reported complete remis-
[27, 28, 42]. sion in only 15% of patients treated with steroids for
less than 4 months, while 61% of patients treated for 4Initial therapy and response
months or more entered a complete remission [37]. The
The initial treatment for primary FSGS in children initial period of daily high-dose steroids also might be
comprises 2 months of oral prednisone. This approach an important factor. In most studies achieving 30%
is the same as that for the treatment of primary nephrotic complete remission rates, a period of high-dose steroids
syndrome, as suggested by the International Study of was maintained for 2 to 3 months before tapering. Rydel
Kidney Disease in Children (ISKDC) [39, 43]. This pro- et al found that patients achieving a remission had re-
tocol has rarely produced complete remission rates in ceived an initial period of high-dose prednisone for a
more than 30% of patients [2]. However, Pei et al [28] significantly longer duration than had non-responders
as well as Cattran and Rao [41] reported complete remis- (median time of 3 months vs. 1 month, respectively)
sion in 44% of children with primary FSGS using a more even though both groups had a similar total duration of
prolonged initial course of prednisone therapy (6 month treatment [33].
median). The 15-year renal survival for patients with a Less than one-third of adults who ultimately achieve
complete remission was 100% compared to 51% in pa- a complete remission do so by 8 weeks of therapy. The
tients who failed to respond [28, 41]. Based on these median time to complete remission is 3 months, with the
findings, they recommended that nephrotic children with majority of patients reaching a complete remission by 9
primary FSGS be treated with a course of steroids for months from the beginning of treatment [28, 32, 33, 41,
45]. The accumulated experience led the Collaborativeas long as 6 months.
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Table 5. Response to cytotoxic and cyclosporine A therapyGroup of the Socie´te´ de Ne´phrologie to propose that
steroid resistance in adults be defined as the persistence Complete Partial No
Initial response to steroids N remission remission responseof the nephrotic syndrome after a 4-month trial of ther-
Cytotoxic therapyapy with prednisone at a dose of 1 mg/kg/day [46].
Steroid-responsive 43 22 (51%) 10 (23%) 11 (26%)Although the presence of the cellular lesion generally
Steroid-resistant 185 31 (17%) 27 (15%) 127 (69%)
has been associated with a poor therapeutic response, Cyclosporine A therapy
Steroid-responsive 15 11 (73%) 1 (7%) 3 (20%)with remissions in fewer than 20% of treated patients
Steroid-resistant 281 82 (29%) 61 (22%) 138 (49%)[10, 26, 38], we have observed no difference in the remis-
Reproduced with permission from Ref. 2.sion rate for patients with cellular FSGS compared to
patients with classic FSGS (52% with cellular FSGS vs.
53% with classic FSGS) [27]. However, the remission
rate was only 23% in patients whose biopsies demon-
could be sufficient. In patients who are frequent relapsers
strated 20% involvement of glomeruli with cellular
or steroid-dependent, or in patients in whom a more
lesions [27]. The reason for the different response rates
steroid-conservative approach is desired, the use of cyto-among studies is not clear but might relate to differences
toxic agents or cyclosporine A (CsA) has been beneficial.in therapeutic approach and to the presence of more
A course of cytotoxic therapy (cyclophosphamide, 2advanced renal disease in the patients in the studies
mg/kg/day, or chlorambucil, 0.1 to 0.2 mg/kg/day for 2documenting a poor response [10, 26, 30].
to 3 months), often in combination with prednisone,Some have advocated alternate-day steroid therapy to
leads to the re-establishment of a remission in more thanminimize the potential for complications associated with
70% of patients (Table 5). Response to these agents isdaily steroid administration. Although the response to
associated with a reduction in the rate of relapse and inhigh-dose alternate-day steroids has been disappointing
more prolonged remissions, thus eliminating the needin young adults [47], Nagai et al attained complete remis-
for additional courses of steroids [37, 45, 50, 51].sion in 44% of elderly (60 years of age) nephrotic
Cyclosporine A is also highly successful in steroid-patients with primary FSGS using 1.0 to 1.6 mg/kg (up
responsive patients who subsequently relapse; a responseto 100 mg) every other day for 3 to 5 months [48]. Over
is seen within the first month on treatment in the majority37 months of follow-up, no relapses occurred and no
of patients (Table 5). Unfortunately, more than 75% ofpatient with a complete remission progressed to ESRD,
patients relapse within 2 months of taper or discontinua-compared to 47% of untreated or non-responsive pa-
tion of the drug [52–56]. This can result in CsA depen-tients. Furthermore, the therapy was well tolerated with-
dency and the potential for CsA-induced nephrotoxicityout obvious complications.
[46]. Thus, for the frequently relapsing or steroid-depen-Approximately 20% of adults have received cytotoxic
dent FSGS patient, a course of therapy with a cytotoxicagents along with steroids as initial therapy, but this
agent likely offers the greatest overall benefit.regimen appears to confer no added benefit in attaining
a complete remission when compared to steroids alone Treatment of steroid-resistant patients
[37, 45]. However, their use has been associated with
In children initially resistant to the standard course offewer relapses and a more stable remission than steroids
steroid therapy, a more intense course of treatment withalone [37, 45].
pulse methylprednisolone and alkylating agents has been
utilized. In uncontrolled trials using this aggressive pro-Treatment of relapsing patients
tocol, Tune et al reported remission rates of 60% inThe improved outcome incurred by a remission in
steroid-resistant children with FSGS [36]. However, theprimary FSGS depends on that remission being sus-
same degree of success with pulse-methylprednisolonetained, as recurrence of the nephrotic syndrome portends
therapy has not been experienced by others [36].a prognosis similar to that in primary non-responders
Alternate therapeutic approaches in steroid-resistant[31, 49]. The duration of the initial remission is longer
patients with FSGS are the same as those in steroid-and overall relapse rate is less in adults than children
responsive patients (that is, cyclophosphamide or chlor-(25 vs. 80%) [28, 41]. Fortunately for patients who re-
ambucil, and CsA). Unfortunately, the response to theselapse, the majority (75%) is able to achieve a second
agents in steroid-resistant FSGS has been disappointingremission with retreatment [28, 41, 45]. Patients who
in adults and children when compared to that of steroid-remain in remission for 10 years have an excellent
responsive patients (Table 5). In the only prospectiveprognosis and are unlikely to relapse subsequently [50].
randomized trial evaluating the benefit of cyclophos-The therapeutic approach to the patient who relapses
phamide in steroid-resistant children with FSGS, cyclo-depends on the frequency with which relapses occur. In
phosphamide achieved no better response than did a pro-the patient who relapses after a prolonged period off
steroids (6 months), a second course of steroid therapy longed course of alternate-day prednisone alone [57].
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Recently, mycophenolate mofetil has been tried in a been highly successful in the treatment of recurrent
FSGS in renal transplant patients [19, 20]. Unfortunately,small number of adults with steroid-resistant FSGS and
has produced improvement in proteinuria and stabili- the limited experience with plasmapheresis in primary
FSGS has not met with the same beneficial resultszation of renal function, but it has not yielded complete
remissions (abstract; Radhakrishan et al, J Am Soc Neph- [68–71].
rol 10:114A, 1999) [58].
ConclusionsThe use of CsA in steroid-resistant FSGS has resulted
in somewhat more favorable results than did cytotoxic The use of ACE inhibitors (or ARBs) along with good
blood pressure control should be part of the therapeuticagents (Table 5). Low-dose prednisone combined with
CsA might enhance the likelihood of remission [59]. approach for all patients with primary glomerulopathies,
nephrotic or non-nephrotic, and particularly in thoseHowever, if a response to CsA isn’t observed by 4 to 6
months, it is unlikely to occur [54]. Prospective random- with FSGS. In nephrotic patients with primary FSGS,
recent experience has provided a note of optimism in theized controlled trials of CsA (3.5 to 6.0 mg/kg/day, in
two divided doses, for 6 months) have been conducted in use of immunosuppressive agents in treating this other-
wise progressive glomerulopathy. As a result, a courseadults [44, 55] and children [55, 60] with steroid-resistant
FSGS. In the two studies that primarily evaluated adults of steroid therapy in primary FSGS is warranted in ne-
phrotic patients who have reasonably well-preserved re-[44, 55], the complete remission rate was only 13% and
21%, but none of the patients in the control group nal function (serum creatinine 3 mg/dL) in whom it is
not otherwise contraindicated. As an initial approach toachieved a complete remission. In every study, patients
treated with CsA had a significantly higher remission treatment in adults, high-dose prednisone is given for 3
to 4 months. In the elderly, an initial alternate-day regi-rate than did patients in the control group. After discon-
tinuation of CsA, 60% of patients followed by Cattran men of high-dose prednisone given for 4 to 5 months
can be used. In patients showing a response to treatment,et al [44] and 75% of patients followed by Ponticelli
et al [55] had relapsed by 12 months. Nonetheless, at 50 the dose can be slowly tapered over an additional 3
months of follow-up, Cattran et al found that creatinine months. For patients unresponsive to the initial course
clearance was reduced by 50% in only 25% of CsA- of therapy, a more rapid taper, over 4 weeks, could be
treated patients compared to 52% of patients on placebo, utilized to minimize further steroid exposure.
and the renal survival at 4 years was 72% in the CsA In relapsing or steroid-dependent patients, a 2- to
group compared to 49% in the placebo group. Thus, 3-month course of cytotoxic agents appears most benefi-
continuation of CsA therapy is required to maintain the cial in achieving a more sustained remission. The use of
remission in proteinuria, but even with relapse, a benefi- CsA in this setting is also effective but risks the likelihood
cial effect resulting in the preservation of renal function of CsA nephrotoxicity from long-term CsA dependency.
is observed in some patients. Whether prolonged use of In patients who are steroid-resistant, CsA appears to
low-dose CsA, required to maintain a remission in some have a better overall response rate than cytotoxic agents.
patients, is less nephrotoxic is not known and needs to Since relapse is common after CsA is discontinued, pa-
be evaluated [61]. Patients remaining in remission on tients might require a more prolonged course of CsA to
CsA for more than 12 months can be slowly tapered off maintain a remission. Ideally, this should be done with
CsA without subsequent relapse [46]. Thus, one should the lowest dose possible to minimize potential nephro-
attempt to taper CsA in patients with a prolonged remis- toxicity. Patients in remission for 12 months on CsA
sion to minimize the potential for nephrotoxicity. can be successfully tapered without relapse.
Other treatment considerations
QUESTIONS AND ANSWERSControl of blood pressure and the use of angiotensin-
Dr. Nicolaos E. Madias (Executive Academic Dean,converting-enzyme (ACE) inhibitors and angiotensin II
Tuft University School of Medicine, Boston, Massachu-receptor blockers (ARBs) reduce proteinuria and the
setts, USA): What is known about the effects of steroidsrate of decline in glomerular filtration rate by as much
and other immunosuppressive agents on serum perme-as 50% in patients with primary glomerulopathies, in-
ability activity and podocyte injury?cluding FSGS [62–66]. However, these measures alone
Dr. Korbet: Steroids and immunosuppressive agentshave rarely led to remission of nephrotic syndrome in
such as cyclophosphamide and cyclosporine act either bypatients with primary FSGS [64, 67]. Irrespective of
decreasing the production of the permeability factor bythat, the treatment both for nephrotic and non-nephrotic
the immune system or by altering the effect of this factorpatients with primary FSGS must include good blood
at the level of the podocyte. I am not aware of any studiespressure control and the use of ACE inhibitors (and/or
specifically looking at the effect of steroids or immuno-ARBs).
The use of plasmapheresis or immunoadsorption has suppressive agents on the level of the permeability factor
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in patients who have attained a remission with these been attributed to ischemic injury secondary to hemo-
dynamic alterations resulting in part from low serumtherapies. However, some experimental data do suggest
that steroids have a direct effect on the podocytes that oncotic pressure, particularly in patients with vascular
compromise [73]. Additionally, Lowenstein and his col-can protect and enhance recovery from adriamycin or
puromycin aminonucleoside-induced nephrotic syndrome leagues suggested that increased interstitial edema also
plays a role [74]. Although acute renal failure (ARF) is(abstracts; Li XZ, J Am Soc Nephrol 12:656A, 2001;
Ransom RF, J Am Soc Nephrol 12:576A, 2001). Cy- most often seen in patients with minimal-change disease,
it also has been described in patients with FSGS. Acuteclosporine also protects glomeruli in vitro from the ef-
fects of the permeability factor, and this protection is renal failure most often occurs within the first month
after the patient presents with the nephrotic syndrome.believed to be secondary to an increase in glomerular
cyclic AMP [72]. The ARF generally resolves over four to eight weeks
and such resolution is usually associated with response toDr. Madias: Can you summarize for us what is known
about the genetic defects of familial forms of FSGS? steroid therapy and/or albumin infusions and aggressive
diuresis. Our patient was given high-dose steroids andHas such knowledge produced any new insights into the
pathogenesis of the entity? for a short time also received albumin infusions in addi-
tion to aggressive diuresis with loop diuretics. Her acuteDr. Korbet: A number of forms of familial FSGS
are a result of genetic mutations of various membrane renal failure subsequently resolved. It is of interest that
as her serum creatinine concentration normalized, theproteins expressed by the podocyte that are important in
protein trafficking. Mutations of podocin, alpha-actinin, proteinuria worsened, most likely because of improved
glomerular filtration; the proteinuria then improved asand CD2-associated protein, as well as mutations of the
Wilms’ tumor gene, all have been associated with the de- she responded to steroid therapy.
Dr. Harrington: What is the normal role of podocin?velopment of focal segmental glomerulosclerosis [14, 17].
Mutations of the podocin gene found on chromosome Also, are there knockout models for the podocin gene
that might give us hints as to what’s going on in FSGS?1q are inherited in an autosomal recessive fashion, and
mutations of the alpha-actinin 4 gene are inherited in Dr. Korbet: Podocin, along with nephrin and CD2-
associated protein, is an integral component of the slitan autosomal dominant fashion and are linked to chro-
mosome 19q. These familial forms of FSGS are associ- diaphragm and therefore is involved in protein traffick-
ing [75]. There are knock-out models in mice for nephrinated with steroid resistance and with progression to end-
stage renal disease, but unlike the sporadic forms of and CD2-associated protein, but I am not aware of one
for podocin. Nonetheless, as I said, mutations in theFSGS associated with the permeability factor, these in-
herited forms of FSGS do not recur after renal trans- podocin gene have resulted in podocyte injury that has
led to familial as well as sporadic forms of FSGS.plantation [17]. Thus, the pathogenesis of FSGS in pa-
tients with familial FSGS can differ significantly from Dr. Ronald D. Perrone (Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Ithat of patients with sporadic forms of FSGS. This under-
scores the fact that focal segmental glomerulosclerosis think you implied that the response to therapy is the only
parameter that implies success. Are there any features onis merely a pattern of injury that can result from a num-
ber of pathogenetic mechanisms that have differing prog- the biopsy, other than the degree of fibrosis, which might
predict response to therapy or that might rule out somenostic and therapeutic implications. It is of interest that
sporadic forms of FSGS secondary to mutations in po- other genetic disorder?
Dr. Korbet: The attainment of a remission in patientsdocin are now being recognized [17]. Thus, when avail-
able, genetic screening for these various mutations will with FSGS is associated with a substantial risk reduction
in the progression to end-stage renal disease. We [27]become an integral part in the evaluation of patients
with FSGS. and others [23, 37] have shown that nephrotic patients
with primary FSGS having20% interstitial fibrosis areDr. John T. Harrington (Dean,Tufts UniversitySchool
of Medicine): The patient you presented had ATN on significantly more likely to progress to end-stage renal
disease as are patients with the cellular lesion. Steroidbiopsy. What’s your explanation for the acute tubular
necrosis in this patient? treatment is the only covariate found to be an indepen-
dent predictor of whether a patient will achieve a remis-Dr. Korbet: Acute renal failure occurs in patients
with the nephrotic syndrome and is associated with acute sion [27, 37]. The only histologic variable that we found
to be a negative predictor of remission was the presencetubular necrosis in the majority of cases [73]. This compli-
cation most often occurs in patients with serum albumin of 20% cellular lesions in the biopsy specimen [27].
Nonetheless, even in these patients a remission was at-levels of 2 g/dL, as in today’s patient, and also occurs
more commonly in older patients and patients with sub- tained in 23%. With regard to the issue of whether histo-
logic features would allow one to differentiate geneticstantial vascular disease on the renal biopsy. The patho-
genesis of the acute tubular necrosis is unknown but has from sporadic forms of FSGS, I am unaware of any.
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Dr. Madias: To what extent might the poor correla- an extremely high incidence of HIV in those patients.
Has that been true in your experience or in the US intion between histology and clinical outcome be influ-
enced by the limited information on the extent of injury general?
Dr. Korbet: Patients with idiopathic FSGS who havethat is provided by single-section (as opposed to serial-
section) biopsies? the cellular or collapsing lesion have massive proteinuria
(10 g/day) in up to 70% of cases, but this concurrenceDr. Korbet: The histologic features most associated
with progressive renal disease in patients with primary is seen in only approximately 10% of patients with classic
FSGS [30]. Since collapsing glomerulopathy is the lesionFSGS are first and foremost the degree of interstitial
fibrosis, and second, the presence of cellular lesions [27]. associated with HIV-associated nephropathy, it wouldn’t
be surprising that these patients also often have high-Fogo et al have shown that the number of segmentally
scarred glomeruli found in renal biopsies of nephrotic grade proteinuria. We screen all patients who have pri-
mary FSGS for HIV. In our experience in a private hos-patients with primary FSGS is increased by 50% when
serial biopsy sections are compared to the standard sin- pital in Chicago, 2% of all patients with FSGS have
HIV. Valerie et al have reported that 14% of all patientsgle-section assessment [76]. Unfortunately, it is unknown
whether the serial-section approach to evaluating renal with FSGS in their New York experience have HIV
(abstract; Barisoni, J Am Soc Nephrol 5:347, 1994). Thisbiopsies in FSGS would result in a significant correlation
between the proportion of segmentally involved glomer- variance most likely reflects differences in patient mix.
Dr. Perrone: If you were able to distribute an unlim-uli and clinical outcome, as this was not evaluated in this
study. Furthermore, there was no attempt to determine ited pot of money and direct research in this area, what
would you fund? Podocyte biology? Permeability fac-whether a correlation existed between the proportion
of segmentally sclerosed glomeruli and the degree of tors? Molecular genetics?
Dr. Korbet: I think research into each of these areasinterstitial fibrosis.
Dr. James Strom (Division of Nephrology, St. Eliza- is equally important, as we are finding the pathogenesis
of FSGS to be quite diverse.beth’s Medical Center, Brighton, Massachusetts): In the
older literature, idiopathic collapsing GN has a nearly Dr. Madias: What are the predictors of recurrence of
FSGS in the graft?hopeless prognosis. Do you believe that this is because
these cases represented diffuse epithelial cell disease with, Dr. Korbet: Risk factors for the recurrence of FSGS
include recurrence in a previous transplant, white orfor example, 80% collapsing lesions? Should we direct
our therapy differently in this sort of patient? Hispanic race, and patients with malignant FSGS [78].
The value of the level of permeability factor activity inDr. Korbet: Patients with cellular or collapsing FSGS
do have a more progressive form of disease and thus have predicting recurrence also has been evaluated. While
some researchers have shown a correlation between thea poorer prognosis [30]. However, patients with the cellu-
lar or collapsing variant of FSGS who attain and sustain level of the permeability factor activity and recurrent
disease [18], this result has not been seen in all studies;a remission in proteinuria have the same excellent prog-
nosis as do patients with classic FSGS. We found that thus, the predictive value of this assay remains unclear
[79]. Furthermore, this assay is still a research tool andmore than 50% of patients with the cellular lesion attain
a remission with therapy, but previous studies found re- not available for general use.
Dr. Madias: What about the origin of the graft?mission rates of20% [30]. The difference in our experi-
ences might be because in studies reporting a poor re- Dr. Korbet: There appears to be some debate on whe-
ther the use of a living donor or a highly matched donorsponse, patients had more widespread involvement with
cellular lesions, a greater proportion of patients had sig- is associated with a higher incidence of recurrent FSGS
[78]. Recent findings demonstrate no long-term survivalnificant interstitial fibrosis, and more patients had ad-
vanced renal disease than did patients in our study [30]. advantage associated with a living-donor transplant in
children with FSGS [80]. Despite this, there still mightConsistent with this observation is the fact that we too
found that patients with cellular lesions involving20% be other benefits to living donor transplants in children
that might justify the use of such donors for childrenof glomeruli were less likely to respond to steroid therapy
[27]. Thus, patients with less-advanced disease are more with FSGS [18]. In adults with FSGS, living donor trans-
plants are associated with significantly better renal sur-likely to respond to a course of therapy. Whether these
patients respond better to cyclosporine, as has been sug- vival compared to cadaveric donor transplants [81]. Thus,
it would seem that living donor renal transplants aregested, is still unclear, as the experience is extremely
limited [10]. preferable in patients with primary FSGS. The use of a
living donor is not indicated in patients at high risk forDr. Harrington: Several years ago, in a CPC at the
Greek Society of Nephrology, I defined “supernephrotic” recurrent FSGS, such as patients with a history of malig-
nant FSGS or patients who have had recurrent FSGS.syndrome as a disease in patients 20 g/day of protein
[77]. In my review of the literature at the time, I found Dr. Harrington: Other than the 5/6 nephrectomy
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20. Artero ML, Sharma R, Savin V, Vincenti F: Plasmapheresismodel, are there any good animal models of FSGS that
reduces proteinuria and serum capacity to injure glomeruli in pa-
we can utilize to determine best therapy? tients with recurrent focal glomerulosclerosis. Am J Kidney Dis
23:574–581, 1994Dr. Korbet: There is no animal model for primary
21. Verani R, Hawkins EP: Recurrent focal segmental glomerulo-FSGS. At present, patients with recurrent FSGS offer
sclerosis. A pathological study of the early lesion. Am J Nephrol
the best opportunity for us to evaluate the pathogenesis, 6:263–270, 1986
22. Korbet SM, Schwartz MM, Lewis EJ: Recurrent nephrotic syn-histology, and response to treatment in primary FSGS.
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